Provectus Biopharmaceuticals Inc (PVCT)

[Fruno]

Phase 3 protocol posted on Clinicaltrials.gov

New CTD post has the link. http://clinicaltrials.gov/ct2/show/NCT02288897?term=provectus&recr=Open&rank=2

Why is the study limited to patients with no more than 20 lesions? Also confused by the reference to 25 lesions ("Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at Day 29 (Week 5) and/or Day 57 (Week 9) for treatment of any existing disease on the skin (not exceeding 25 Study Lesions) and thereafter at 28-day intervals until complete response, disease progression or study termination occurs.")